Enalozid (enalapril, hydrochlorothiazide) tablets 25 mg. №20

Description

Enalozid 25 mg. Storage
active substances: enalapril maleate, hydrochlorothiazide;

1 tablet contains 100% of the substance: enalapril maleate 10 mg, hydrochlorothiazide 25 mg;

Enalozid 25 mg. Excipients: lactose monohydrate, potato starch, povidone, calcium stearate.

Enalozid 25 mg. Dosage form
Tablets.

Basic physical and chemical properties: tablets from white to yellow-white color with a flat surface, a facet and a line.

Pharmacotherapeutic group
Combined drugs of angiotensin-converting enzyme (ACE) inhibitors. ACE inhibitors and diuretics.

ATX code C09B A02.

Pharmacological properties

Pharmacodynamics.

Enaloside® 25 is a combination of an angiotensin-converting enzyme inhibitor (enalapril maleate) and a diuretic (hydrochlorothiazide).

Angiotensin converting enzyme (ACE) is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the pressor substance angiotensin II. After absorption, enalapril is hydrolyzed to enalaprilat, which inhibits ACE inhibitors. Inhibition of ACE leads to a decrease in plasma angiotensin II levels, leading to increased plasma renin activity (due to inhibition of negative feedback during renin release) and decreased aldosterone secretion.

ACE is identical to kininase II. Enalapril can also block the breakdown of bradykinin, which is a potent vasodepressant peptide. However, the role of this fact in the therapeutic effects of enalapril remains unknown. While the mechanism by which enalapril lowers blood pressure is primarily associated with inhibition of the renin-angiotensin-aldosterone system, which plays a major role in regulating blood pressure, enalapril may have an antihypertensive effect even in patients with low-renin hypertension.

Hydrochlorothiazide is a diuretic and antihypertensive agent that increases the activity of plasma renin. The antihypertensive effects of the two components are additive and usually last for 24 hours. Although enalapril alone has an antihypertensive effect even in patients with low-renin hypertension, co-administration with hydrochlorothiazide in such patients results in a greater reduction in blood pressure. The enalapril component of the drug generally reduces the reduction in potassium caused by hydrochlorothiazide.

Indication
Treatment of hypertension in patients receiving combination therapy.

Contraindication
Hypersensitivity to the active substance or any other component of the drug.
Severe renal impairment (creatinine clearance ≤ 30 ml / min).
Hypokalemia resistant to treatment.
Symptomatic hyperuricemia (gout).
Anury.
A history of angioneurotic edema associated with the use of ACE inhibitors.
Hereditary or idiopathic angioneurotic edema.
Hypersensitivity to drugs that are derivatives of sulfonamides.
Pregnant women or women planning to become pregnant (see “Use during pregnancy or breast-feeding”);
Severe hepatic impairment.
Concomitant use of Enaloside® 25 with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml / min / 1.7Zm2) (see section “Interaction with other medicinal products and other forms of interaction”).